Joe Catanzaro

Kelly Shi

Louise Chen

Thomas Smith

- Konnect Biopharma (CNTB) is strategically focusing its lead product, **Rademikabart**, an IL-4 receptor alpha antibody, on the treatment of **acute exacerbations of asthma and COPD** due to its rapid onset of effect and differentiated safety profile compared to DUPIXENT.  **[1835268_tx_380807_0]** **[1835268_tx_380807_1]** 
- The company is currently conducting **two parallel Phase 2 studies** for acute exacerbations in asthma and COPD, with top-line data anticipated in **H1 2026**.  **[1835268_tx_380807_2]** **[1835268_tx_380807_5]** 
- Rademikabart targets a significant unmet need, as there have been no new drugs for acute exacerbations in over **30 years**, with an addressable market of approximately **4 million patients** annually in the US.  **[1835268_tx_380807_1]** 
- As of **Q2 2025**, CNTB reported approximately **$72 million** in cash, which is expected to fund current trials and extend its cash runway into **2027**.  **[1835268_tx_380807_5]**

Connect Biopharma Holdings (CNTB)